Abhinav Mittal, MD
Pulmonary Disease · Tucson, AZNPI 1538555388
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $370,620 of the $569,744 with a category attached, or 65.1%. Intuitive Surgical accounts for 95.6% of it on its own, with 35 other manufacturers making up the rest. Reporting peaked in 2024 at $320,453 and has fallen 54.1% since, to $147,024 in 2025. Among pulmonary disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 983 payments — averaging $579.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$544K
- Boston Scientific$8K
- ERBE USA Inc$3K
- Medtronic$3K
- Covidien LP$2K
- Pinnacle Biologics, Inc$2K
- plus $7K from 30 others
What the payments were for
- Speaking & faculty fees$370,62065%
- Grants$8,3331%
- Travel & lodging$60,91811%
- Food & beverage$28,7745%
- Education$101,05318%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 700 | $544,447 |
| Boston Scientific | 3 | $8,413 |
| ERBE USA Inc | 1 | $3,000 |
| Medtronic | 34 | $2,890 |
| Covidien LP | 11 | $2,429 |
| Pinnacle Biologics, Inc | 18 | $2,056 |
| Steris Corporation | 4 | $1,515 |
| AstraZeneca | 16 | $887 |
| GSK | 48 | $679 |
| Siemens Medical Solutions USA, Inc. | 3 | $392 |
| Electromed, Inc. | 35 | $354 |
| Teleflex LLC | 5 | $286 |
| Sanofi | 15 | $277 |
| Pulmonx Corporation | 4 | $199 |
| Insmed, Inc. | 9 | $196 |
| Grifols USA, LLC | 10 | $191 |
| Pfizer | 5 | $182 |
| Merck | 7 | $153 |
| Amgen | 8 | $139 |
| Boehringer Ingelheim | 6 | $138 |
| Viatris Specialty LLC | 5 | $124 |
| Verona Pharma, Inc. | 4 | $122 |
| Actelion Pharmaceuticals US, Inc. | 5 | $118 |
| Genentech USA, Inc. | 4 | $106 |
| Karyopharm Therapeutics Inc. | 5 | $84 |
| Baxter Healthcare | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
| Jazz Pharmaceuticals Inc. | 2 | $51 |
| Olympus America Inc. | 1 | $45 |
| Seagen Inc. | 2 | $36 |
| Atricure, Inc. | 1 | $28 |
| Ambu Inc. | 1 | $26 |
| Cook Medical LLC | 2 | $23 |
| Mylan Specialty L.p. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$492,509
- DA VINCI SP$45,049
- GENERAL - BILIARY DEVICES$8,333
- VIO Cryo APC$3,000
- ILLUMISITE$2,097
- superDimension$2,020
- Photofrin$1,461
- TRUFREEZE$1,383
- TEZSPIRE$522
- FASENRA$522
- AIRSUPRA$365
- BREZTRI$345
- Arrow$142
- Signia$127
- CHARTIS CATHETER$119
- ZEPHYR DELIVERY CATHETER$119
- ZEPHYR ENDOBRONCHIAL VALVE$119
- PULMONX CHARTIS TABLET CONSOLE$119
- ELIQUIS$102
How this compares
$569,744 in reported general payments places this provider in the 95th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 138 | $101,936 |
| NucalaMepolizumab | 13 | $48,854 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 58 | $45,501 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $13,366 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $8,329 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,159 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,749 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $6,498 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $4,988 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 109 | $2,007 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,559 |
| Montelukast Sodium | 144 | $1,293 |
| Azithromycin | 11 | $166 |
| Prednisone | 45 | $163 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $140 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta | $679 | $166,868184 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $887 | $50,49079 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $138 | $21,52541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Tucson
- Sachin ChaudharyTucson$90K
- Billie BixbyTucson$35K
- Todd LocherTucson$25K
- Ravi ChandranTucson$13K
- James KneplerTucson$12K
- Ubair AhmedTucson$10K
- George ParidesMesa$913K
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.